<DOC>
	<DOCNO>NCT01548924</DOCNO>
	<brief_summary>The investigator plan study determination dose combination antiangiogenic effect dovitinib cytotoxic activity weekly paclitaxel different type malignant tumor .</brief_summary>
	<brief_title>Determination Dose Antiangiogenic Multitargeted DOVITINIB ( TKI258 ) Plus Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description>This open label , multicenter , Phase I dose escalation study phase dovitinib alone pharmacokinetic profile treatment phase evaluate safety tolerability oral ( po ) dovitinib paclitaxel administer intravenously ( iv ) ( 80 mg/m2 day 1 , 8 , 15 21 every 4 week ) patient malignant tumor histologically confirm , susceptible cure , treat available reference .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Have sign inform consent study willing undergo imageguided biopsy blood sample FC . Men woman 18 year . Patients solid tumor locally advance metastatic confirm histological method cytological , susceptible cure , receive standard treatment available . Participation patient active malignancy . measurable nonmeasurable disease version 1.1. RECIST Class 0 2 ECOG Have least four week elapse since last normal experimental antitumor treatment ( six week BCNU , CCNU mitomycin C ) Have recover toxicity ( except alopecia ) grade 0 1 accord common terminology criterion adverse event National Cancer Institute ( NCI CTCAE , version 4.0 ) . Life expectancy three month . Participation patient active malignancy . The baseline analytical data require : Absolute neutrophil count ( ANC ) ≥ 1.500/mm3 [ 1.5 x 109/l ] Platelets ≥ 75.000/mm3 [ 75 x 109/l ] Hemoglobin ≥ 8.0 g / dL [ 80 g/l ] Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Bilirubin ≤ 1.5 x ULN . AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN ( without liver metastasis ) Concentration electrolyte : Potassium &lt; LIN ( 3.0 mmol/l ) &gt; ULN ( 5.5 mmol/l ) Sodium &lt; LIN ( 130 mmol/l ) &gt; ULN ( 150 mmol/l ) Women childbearing potential must negative pregnancy test within 7 day prior inclusion study . Concomitant treatment another investigational drug within 28 day baseline visit . Have treat dovitinib . Women childbearing age biologically capable conceive use two contraceptive method effective . Highly effective contraceptive method ( condom spermicide , diaphragm spermicide , intrauterine device ) use sex study maintain 8 week end study treatment . Oral contraceptive , implantable , injectable may affect interaction cytochrome P450 , consider effective study . Women childbearing age , define sexually mature hysterectomy reach natural menopause le 12 consecutive month ( i.e. , menses time last 12 month ) must negative pregnancy test within 72 hour start treatment TKI258 . Clinically significant heart disease ( class III IV New York Heart Association ) impair cardiac function , comprise follow : LVEF le 50 % low limit normal ( whichever great ) evaluate two echocardiography ( ECO ) , 45 % low limit normal ( whichever great ) ventriculography equilibrium radionuclide ( MUGA ) leave bundle branch block Use cardiac pacemaker must Congenital Long QT Syndrome History presence ventricular tachyarrhythmia Presence unstable atrial fibrillation ( ventricular rate &gt; 100 bpm ) . Patients stable atrial fibrillation may participate provide meet cardiac exclusion criterion . clinically significant rest bradycardia ( &lt; 50 bpm ) Uncontrolled hypertension ( systolic pressure ≥ 150 mm Hg diastolic pressure ≥ 100 mm Hg , without antihypertensive medication ) . QTc &gt; 480 m ECG screen Right bundle branch block leave anterior hemiblock ( bifascicular block ) Angina pectoris three month prior start study treatment Acute myocardial infarction three month prior start study treatment Other clinically significant heart disease ( eg. , Congestive heart failure [ CHF ] , history labile hypertension poor compliance history pattern antihypertensive ) Have uncontrolled infection . Diabetes mellitus ( insulin insulinoindependiente , need chronic medication ) sign clinically significant peripheral vascular disease . History pericarditis , pleural effusion clinically important 12 month precede current ascites require two intervention per month ( increase dose expansion ) . clinically significant disorder hypothalamicpituitary , adrenal thyroid gland . History acute chronic pancreatitis cause . acute chronic liver disease chronic liver disease kind . Malabsorption syndrome uncontrolled gastrointestinal toxicity ( nausea , diarrhea , vomit ) grade 2 NCI CTCAE . Any serious medical psychiatric disorder , acute chronic , analytical failure increase risk associate participation study drug test interfere interpretation study result , opinion investigator , prevent participation . Treatment drug prolong QT interval ( Appendix C ) polymorphic ventricular tachycardia cause suspend replaced different drug study treatment . Treatment ketoconazole , erythromycin , carbamazepine , phenobarbital , rifampicin , phenytoin , quinidine two week baseline . Major surgery within 28 day start study treatment , recover effect major operation . Diagnosis HIV infection ( HIV test mandatory ) . History another primary malignancy currently clinical require active intervention . Patients brain metastasis detect image study ( CT , MRI ) Alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Patients malignant solid tumor histologically confirm , susceptible cure , receive standard treatment available</keyword>
</DOC>